REGENXBIO announced positive long-term results for surabgene lomparvovec (sura-vec), a one-time gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). Wet AMD patients showed stable or improved vision through five years, reducing the need for frequent anti-VEGF injections, with no drug-related inflammation. In diabetic retinopathy, 55% of patients had significant disease severity improvement at 2.5 years, with no vision-threatening events and no inflammation observed. Topline data from ongoing pivotal trials are expected in Q4 2026, potentially changing treatment by reducing injection burdens and preserving vision long-term.
Meta, led by Mark Zuckerberg, plans to begin production of its in-house Iris AI chip in September. This move is part of Meta's strategy to double its computing capacity to 14 gigawatts, enhancing its AI and data processing capabilities. The new chip ...
The 2026 Enbridge Tour Alberta for Cancer saw over 2,300 cyclists raise a record-breaking $12.5 million to support cancer care in Alberta. The funds will be invested by the Alberta Cancer Foundation into advanced cancer research, clinical trials, and...
Cardano founder Charles Hoskinson announced a 2026 plan to integrate $1.6 trillion of idle Bitcoin into Cardano's DeFi ecosystem through a platform called Pogun. The platform will launch in three phases, enabling Bitcoin lending, yield earning, and t...
Taylor Farms is voluntarily recalling iceberg lettuce sourced from central Mexico across 27 U.S. states due to potential contamination with the Cyclospora parasite, linked to an outbreak traced to Taco Bell shredded lettuce. The recall covers product...
Michael Saylor published a detailed critique rejecting Bitcoin's BIP 110 softfork proposal, which aims to restrict certain non-payment transactions temporarily. He warns the proposal's low 55% miner approval threshold could increase the risk of a blo...
